Viridian Therapeutics Inc
$ 19.90
0.10%
30 Jul - close price
- Market Cap 2,195,302,000 USD
- Current Price $ 19.90
- High / Low $ 20.00 / 19.29
- Stock P/E N/A
- Book Value 4.92
- EPS -3.42
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.58 %
- 52 Week High 34.29
- 52 Week Low 13.18
About
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$36.12
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-26 | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-27 | 2024-11-12 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-13 | 2023-08-08 |
| Reported EPS | -0.9 | -1.08 | -0.34 | -1 | -0.87 | -0.81 | -1.15 | -1.02 | -0.79 | -1.35 | -1.09 | -1.27 |
| Estimated EPS | -1.08 | -0.9 | -0.82 | -0.98 | -0.96 | -1.0442 | -1.05 | -0.92 | -1.1 | -1.03 | -1.24 | -1.26 |
| Surprise | 0.18 | -0.18 | 0.48 | -0.02 | 0.09 | 0.2342 | -0.1 | -0.1 | 0.31 | -0.32 | 0.15 | -0.01 |
| Surprise Percentage | 16.6667% | -20% | 58.5366% | -2.0408% | 9.375% | 22.4287% | -9.5238% | -10.8696% | 28.1818% | -31.068% | 12.0968% | -0.7937% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.97 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VRDN
2026-07-30 07:39:12
Viridian Therapeutics reported positive topline results from its Elegrobart REVEAL-1 phase III trial for Graves' ophthalmopathy, moving towards a Biologics License Application in early 2027. This development, alongside the approval of LUMVOA, strengthens Viridian's position in the autoimmune eye disease market and validates its investment narrative. While the company remains unprofitable and has diluted shareholders, the recent news significantly bolsters its growth prospects and commercial catalysts despite some market optimism already being priced in.
2026-07-28 15:11:24
This article provides the "Price to earnings forward" value for Viridian Therapeutics, Inc. (LSE:0K1R). The core data presented is a single numerical value for this financial metric, alongside its change and percentage change. The article focuses solely on this specific financial data point for the company.
2026-07-27 13:10:34
This article provides an incomplete revenue breakdown for Viridian Therapeutics Inc (VRDN), stating that much of the relevant data has not yet been disclosed by the company. It does, however, show a regional revenue figure for the United States at $70.85 million with a 0.00% proportion, indicating a potential data entry issue or lack of comprehensive data. The article also provides current stock information for VRDN.
2026-07-27 06:21:06
Viridian Therapeutics Inc. (VRDN) is a biopharmaceutical company specializing in developing medicines for rare diseases, currently focusing on Thyroid Eye Disease (TED) with two global Phase 3 trials for veligrotug and two for VRDN-003. The company is also advancing a portfolio of neonatal Fc receptor inhibitors for autoimmune diseases. Shares are trading at $19.890, up 1.95%, with a market cap of $2.04 billion.
2026-07-26 05:12:31
This article provides a detailed quarterly and annual income statement for Viridian Therapeutics Inc (VRDN), covering various financial metrics from total revenue to basic and diluted earnings per share. It also includes frequently asked questions about how to interpret these statements and key metrics for analyzing the stock.
2026-07-25 17:11:24
This article provides a comprehensive stock analysis of Viridian Therapeutics Inc (VRDN) by TradingKey. It highlights the company's strong fundamentals, significant growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. The analysis notes high institutional ownership, a "Buy" rating from multiple analysts with a target price of $35.33, and ongoing clinical trials for serious diseases like thyroid eye disease.
